A novel bioreducible and pH-responsive magnetic nanohydrogel based on β-cyclodextrin for chemo/hyperthermia therapy of cancer

A new strategy for design and development of a magnetic smart drug delivery system (DDS) based on beta-cyclodextrin (beta-CD) and poly(2-ethyl-2-oxazoline) (PEtOx) was reported. For this purpose, a beta-CD-(I)(7) was acetylated, and then EtOx monomer was grafted onto the acetylated beta-CD-(I)7 through cationic ring-opening polymerization followed by simultaneous crosslinking with amine-end capped Fe3O4 nanoparticles (Fe3O4NH2 NPs) and cystamine to produce a beta-CD-g-(PEtOx)(7)/Fe3O4 as a reductionand pH-responsive magnetic DDS. The developed magnetic nanohydrogel was loaded with doxorubicin hydrochloride (Dox), and its drug loading and encapsulation efficiencies, as well as its pHand reduction-triggered drug release behaviors were investigated. The anticancer activity of the formulated beta-CD-g-(PEtOx)(7)/Fe3O4-Dox was investigated against MCF7 cells. According to the results, the formulated beta-CD-g-(PEtOx)7/Fe3O4-Dox can be considered as an efficient and smart DDS for cancer therapy and diagnosis due to its high drug loading value (74 %), slow and stimuli triggered drug release behavior, and acceptable magnetic properties.

Automated summary

A new strategy for designing and developing a magnetic smart drug delivery system based on beta-cyclodextrin and poly(2-ethyl-2-oxazoline) was reported. The developed system showed high drug loading value, slow and stimuli-triggered drug release behavior, and acceptable magnetic properties, making it a potential efficient and smart drug delivery system for cancer therapy and diagnosis.